This early-stage study tested a new drug called IBC-Ab002 in 40 people with early Alzheimer's disease. The main goal was to see if the drug is safe and how the body processes it. Researchers gave increasing doses of the drug or a placebo to check for side effects and changes in l…
Phase: PHASE1 • Sponsor: Immunobrain Checkpoint • Aim: Symptom relief
Last updated May 07, 2026 18:43 UTC